Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CTT Pharmaceutical HoldingsCTTH -2.22% Intrinsic Value: Projected FCF is $0.01 as of Sep. 02, 2026. The stock has 1 warning sign investors should review. Among 635 Drug Manufacturers companies, CTT Pharmaceutical Holdings ranks worse than 86.14% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
The historical rank and industry rank for CTT Pharmaceutical Holdings's Intrinsic Value: Projected FCF or its related term are showing as below:
CTTH'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 3.42 Med: 6.01 Max: 7.5
Current: 4.89
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of CTT Pharmaceutical Holdings was 7.50. The lowest was 3.42. And the median was 6.01.
CTTH's Price-to-Projected-FCF is ranked worse than 86.14% of 635
companies
in the Drug Manufacturers industry
Industry Median: 1.57
vs CTTH: 4.89
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
CTT Pharmaceutical Holdings's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
0.04889
/
0.01394793880213
=
3.51
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTT Pharmaceutical Holdings Intrinsic Value: Projected FCF Related Terms
CTT Pharmaceutical Holdings Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for CTT Pharmaceutical Holdings's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTTH vs PRFX, UPC, AKAN: Intrinsic Value: Projected FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CTT Pharmaceutical Holdings's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CTT Pharmaceutical Holdings Price-to-Projected-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CTT Pharmaceutical Holdings's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where CTT Pharmaceutical Holdings's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $0.01 mean?
CTT Pharmaceutical Holdings (CTTH) has a Intrinsic Value: Projected FCF of $0.01 as of Sep. 02, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on CTT Pharmaceutical Holdings and its competitors. According to the industry distribution chart, CTT Pharmaceutical Holdings ranks #547 out of 635 companies in the Drug Manufacturers industry, placing it in the top 86.1%.
Is CTT Pharmaceutical Holdings' Intrinsic Value: Projected FCF too high?
CTT Pharmaceutical Holdings' current Intrinsic Value: Projected FCF is $0.01. The Drug Manufacturers industry median Intrinsic Value: Projected FCF is 1.57. CTT Pharmaceutical Holdings' value of $0.01 is 99.4% below this industry median. Based on the distribution chart, CTT Pharmaceutical Holdings ranks #547 out of 635 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does CTT Pharmaceutical Holdings' Intrinsic Value: Projected FCF compare to PRFX and UPC?
According to the Drug Manufacturers industry distribution chart, CTT Pharmaceutical Holdings ranks #547 out of 635 companies for Intrinsic Value: Projected FCF. This places CTT Pharmaceutical Holdings in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.57. CTT Pharmaceutical Holdings' value of $0.01 is 99.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Drug Manufacturers company?
The median Intrinsic Value: Projected FCF among Drug Manufacturers companies is 1.57, based on 635 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CTT Pharmaceutical Holdings's current Intrinsic Value: Projected FCF of $0.01 is 99.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on CTT Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median Intrinsic Value: Projected FCF is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CTT Pharmaceutical Holdings's current Intrinsic Value: Projected FCF is $0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CTT Pharmaceutical Holdings stock overvalued right now?
CTT Pharmaceutical Holdings (CTTH) has a current Intrinsic Value: Projected FCF of $0.01. The current Intrinsic Value: Projected FCF is $0.01 and 99.4% below the Drug Manufacturers industry median of 1.57. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For CTT Pharmaceutical Holdings (CTTH), the current Intrinsic Value: Projected FCF is $0.01 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CTT Pharmaceutical Holdings Inc specializes in drug delivery systems technology within the pharmaceutical industry. Its focus is on fast-dissolving drug delivery systems through the development of oral delivery thin wafers. The company's technology platform includes the development of oral delivery thin wafers to deliver treatment as an alternative to smoking and ingestion. This technology platform target both the human and veterinarian(pet) markets for treatment of many diseases. The Company believes that its technology will be one of the first to gain use in majorly markets such as pain management and smoking cessation. The Oral Thin Film formulation is protected by patents in the USA, Canada, Europe and many other countries across the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTTH has been successfully added to your 
